Martha Hernandez‐Illas

1.1k citations

20 papers · 812 indexed · 2 hit papers · h-index 12

Molecular Medicine top 10%
Endocrinology, Diabetes and Metabolism top 10%
- Diabetes Treatment and Management 3
- Pituitary Gland Disorders and Treatments 2
Pharmacology top 10%
- Pharmacology and Obesity Treatment 2
- Drug-Induced Hepatotoxicity and Protection 2
Applied Microbiology and Biotechnology top 10%
Nephrology top 10%
- Gout, Hyperuricemia, Uric Acid 4
Epidemiology
- Pneumocystis jirovecii pneumonia detection and treatment 2
Surgery
- Lipoproteins and Cardiovascular Health 2
Public Health, Environmental and Occupational Health
- Acute Lymphoblastic Leukemia research 2

Co-authors: Yuling Wu Xiang‐Qing Yu Gabriel J. Robbie Hasan S. Jafri Terramika Bellamy David A. D’Alessio Shweta Urva Tamer Coşkun
Cited by: Molecular Medicine Endocrinology, Diabetes and Metabolism Pharmacology
Partner nations: United States Australia United Kingdom

In The Last Decade

Martha Hernandez‐Illas

18 papers receiving 793 citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2022 Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
2022 LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

Peers

Countries citing papers authored by Martha Hernandez‐Illas

Since Specialization

Citations

This map shows the geographic impact of Martha Hernandez‐Illas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martha Hernandez‐Illas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martha Hernandez‐Illas more than expected).

Fields of papers citing papers by Martha Hernandez‐Illas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martha Hernandez‐Illas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martha Hernandez‐Illas. The network helps show where Martha Hernandez‐Illas may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Martha Hernandez‐Illas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Martha Hernandez‐Illas Line = papers co-authored together Martha Hernandez‐Illas links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Combined GPR40 and GPR119 full agonism with K‐757 and K‐833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM Michael F. Crutchlow,Jiajun Liu,Martha Hernandez‐Illas,Harry Zhang,Anna Arreglado,Annemarie Vance,Donald Boisvert,Giuseppe Terracina,Brett Lauring	2025	0
2	Once‐daily oral small‐molecule glucagon‐like peptide‐1 receptor agonist lotiglipron (PF‐07081532) for type 2 diabetes and obesity: Two randomized, placebo‐controlled, multiple‐ascending‐dose Phase 1 studies Clare Buckeridge,Nikolaos Tsamandouras,Santos Carvajal‐Gonzalez,Lisa Brown,Martha Hernandez‐Illas,Aditi R. Saxena	2024	8
3	LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trialbreakdown → Shweta Urva,Tamer Coşkun,Mei Teng Loh,Yu Du,Melissa K. Thomas,Sirel Gurbuz,Axel Haupt,Charles Benson,Martha Hernandez‐Illas,David A. D’Alessio,Zvonko Miličević	2022	130
4	CRN04894: an oral, nonpeptide adrenocorticotropic hormone (ACTH) receptor antagonist decreases basal and stimulated cortisol secretion in healthy volunteers Peter Trainer,Christine Ferrara-Cook,Alejandro Ayala,Rosa Luo,Stephanie Miller,Yang Wang,Martha Hernandez‐Illas,Struthers R. Scott,Stephen F. Betz,Alan Krasner	2022	1
5	OR12-2 Inhibition of Basal and ACTH-stimulated Cortisol Secretion in Humans Using an Oral Nonpeptide ACTH Antagonist (CRN04894) Stephen F. Betz,Christine Ferrara-Cook,Martha Hernandez‐Illas,Rosa Luo,Ajay Madan,Stephanie Miller,Scott Struthers,Peter Trainer,Yang Wang,Alan Krasner	2022	1
6	Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)breakdown → Michael J. Koren,Patrick M. Moriarty,Seth J. Baum,Joel Neutel,Martha Hernandez‐Illas,Howard Weintraub,Mónica Florio,Helina Kassahun,Stacey Melquist,Tracy Varrieur,Saptarsi M. Haldar,Winnie Sohn,Huei Wang,Mary Elliott‐Davey,Brooke M. Rock,Tao Pei,Oliver Homann,Jennifer Hellawell,Gerald F. Watts	2022	167
7	Abstract 13951: Safety, Tolerability and Efficacy of Single-dose Amg 890, a Novel Sirna Targeting Lp(a), in Healthy Subjects and Subjects With Elevated Lp(a) Michael J. Koren,Patrick M. Moriarty,Joel Neutel,Seth J. Baum,Martha Hernandez‐Illas,Howard Weintraub,Jennifer Hellawell,Tracy Varrieur,Winnie Sohn,Huei Wang,Mary Elliott‐Davey,Helina Kassahun,Gerald F. Watts	2020	25
8	A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP‐458) in Healthy Adult Volunteers Tong Lin,Martha Hernandez‐Illas,Andres Rey,Jack Jenkins,Reddy Chandula,Jeffrey A. Silverman,Mi Rim Choi	2020	15
9	First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody Pascal Espié,Yanling He,Phillip J. Koo,Denise Sickert,Cyrielle Dupuy,Edwige Chokoté,Roland Schuler,Heidi Mergentaler,Jacinda Ristov,Julie Milojevic,Aurélie Verles,Andrea Groenewegen,Anita Auger,Alexandre Avraméas,Michael Rotte,Laurence Colin,Charles Tomek,Martha Hernandez‐Illas,James S. Rush,P Gergely	2019	68
10	A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Healthy Adults Martha Hernandez‐Illas,Tong Lin,Andres Rey,Jack Jenkins,Reddy Chandula,Mi Rim Choi	2019	2
11	Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study R. Fleischmann,Peter Winkle,Jeffrey N. Miner,Xiaohong Yan,Liz Hicks,Shakti Valdez,Jesse Hall,Sha Liu,Zancong Shen,Michael Gillen,Martha Hernandez‐Illas	2018	37
12	Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters Takayuki Katsube,Shiro Miyazaki,Yukitoshi Narukawa,Martha Hernandez‐Illas,Toshihiro Wajima	2018	22
13	Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study Roy Fleischmann,Peter Winkle,Jesse Hall,Shakti Valdez,Sha Liu,Xiaohong Yan,Liz Hicks,Caroline Lee,Jeffrey N. Miner,Michael Gillen,Martha Hernandez‐Illas	2018	11
14	Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults Omar Ali,Xiang‐Qing Yu,Gabriel J. Robbie,Yuling Wu,Kathryn Shoemaker,Li Yu,Antonio DiGiandomenico,Ashley Keller,Chuka Anude,Martha Hernandez‐Illas,Terramika Bellamy,Judith Falloon,Filip Dubovsky,Hasan S. Jafri	2018	92
15	THU0434 Pharmacodynamic effects and safety of verinurad (RDEA3170) in combination with febuxostat versus febuxostat alone in adults with gout: a phase 2a, open-label study Roy Fleischmann,Peter Winkle,John P. Hall,Shakti Valdez,S Liu,Xiao Qiang Yan,Lee G. Hicks,Martha Hernandez‐Illas	2017	1
16	AB0880 Pharmacodynamic effects and safety of verinurad (RDEA3170) in combination with allopurinol versus allopurinol alone in adults with gout: a phase 2a, open-label study Roy Fleischmann,Peter Winkle,JN Miner,Xiao Qiang Yan,Lee G. Hicks,Shakti Valdez,John P. Hall,Martha Hernandez‐Illas	2017	1
17	Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir Rajesh Krishna,Lilly East,Patrick Larson,Chandni Valiathan,Kristin L. Butterfield,Yang Teng,Martha Hernandez‐Illas	2016	18
18	Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults Xiang‐Qing Yu,Gabriel J. Robbie,Yuling Wu,Mark T. Esser,Kathryn Jensen,Howard I. Schwartz,Terramika Bellamy,Martha Hernandez‐Illas,Hasan S. Jafri	2016	104
19	Pharmacokinetics and pharmacodynamics of PF‐05231023, a novel long‐acting FGF21 mimetic, in a first‐in‐human study Jennifer Dong,Michelle I. Rossulek,Veena Somayaji,Daniel Baltrukonis,Yali Liang,Krischan J Hudson,Martha Hernandez‐Illas,Roberto A. Calle	2015	85
20	Recombinant Human Tumor Necrosis Factor Receptor Fc Fusion Protein (Etanercept): Experience as a Therapy for Sight-threatening Scleritis and Sterile Corneal Ulceration Martha Hernandez‐Illas,Elaine C. Tozman,Samuel F. Fulcher,J W Jundt,Janet L. Davis,Stephen C. Pflugfelder	2004	24

About Martha Hernandez‐Illas

Martha Hernandez‐Illas is a scholar working on Nephrology, Endocrinology, Diabetes and Metabolism and Behavioral Neuroscience, having authored 20 papers that have together received 812 indexed citations. Recurring topics across this work include Gout, Hyperuricemia, Uric Acid (4 papers), Diabetes Treatment and Management (3 papers), Pharmacology and Obesity Treatment (2 papers), Pneumocystis jirovecii pneumonia detection and treatment (2 papers), Drug-Induced Hepatotoxicity and Protection (2 papers), Lipoproteins and Cardiovascular Health (2 papers), Pituitary Gland Disorders and Treatments (2 papers) and Acute Lymphoblastic Leukemia research (2 papers). The work is most often cited by research in Molecular Medicine (71 citations), Endocrinology, Diabetes and Metabolism (157 citations) and Pharmacology (120 citations). Martha Hernandez‐Illas has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Yuling Wu, Xiang‐Qing Yu, Gabriel J. Robbie, Hasan S. Jafri, Terramika Bellamy, David A. D’Alessio, Shweta Urva, Tamer Coşkun, Yu Du and Axel Haupt.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact